




RealRate

PHARMACEUTICAL 2019

Sonnet Biotherapeutics Holdings Inc
Rank 252 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 185% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 66% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	1,675
Cost of Goods Sold	0
Intangible Assets	16,404
Liabilities, Current	14,312
Liabilities, Non-Current	3,000
Other Assets	1,247
Other Compr. Net Income	1,078
Other Expenses	40,689
Other Liabilities	4,223
Other Net Income	-2,545
Other Revenues	40,614
Property and Equipment	10,468
Research and Development	0
Selling, General and Administrative Expense	4,579

Output Variable	Value in 1000 USD
Assets	29,793
Liabilities	21,536
Expenses	45,268
Revenues	40,614
Stockholders Equity	8,258
Net Income	-7,199
Comprehensive Net Income	-6,660
BaseVar	70,417
ECR before Limited Liability	44%
Economic Capital Ratio	183%